Hematopoietic Cell Transplant-Comorbidity Index (HCT-CI) Score Predicts Non-Relapse Mortality (NRM) and Overall Survival (OS) in Multiple Myeloma Patients Undergoing Intensive Preparative Regimen with Autologous Stem Cell Transplantation (ASCT) Followed By Maintenance Therapy Using Novel Agents

Introduction: HCT-CI score was initially proposed to predict NRM and survival in allogeneic SCT patients. This was also validated for ASCT by CIBMTR and showed worse survival and NRM in high risk patients. Here, we report results of comorbidity score and its impact specifically in myeloma patients who received intensive preparative regimen consisting of bortezomib, dexamethasone and thalidomide in addition to standard dose Melphalan 200mg/m2 followed by maintenance therapy. Patients and methods: Retrospective analysis was performed on patients receiving autotransplants between March 2012 and December 2016. To investigate the association between HCT-CI patient, disease, and transplant characteristics, chi-squared and Fisher9s exact tests were used. Survival probabilities were estimated and plotted using the Kaplan-Meier method. For OS, time was calculated from transplant to death due to any cause. OS differences were evaluated using the log-rank test. NRM was defined as time from transplant to death due to any cause without prior relapse; relapse was defined as a competing event. Cumulative incidences of NRM were plotted and compared using Gray9s test. Results: 242 patients were included; 88 were > 65 years; 94 were females. Low and intermediate HCT-CI groups were combined and compared against the high risk group. The majority (69 %) were high risk (HCT-CI score ≥3). Only KPS Conclusion: This analysis shows that the HCT-CI score can predict worse NRM and OS in high risk myeloma patients receiving ASCT using intensive preparative regimen. Higher than expected rates of NRM in both groups are likely due to a high incidence of infections and other complications during maintenance therapy, but this treatment approach resulted in very high rates of CR in both groups. Therefore, these results and further analysis could help to better stratify and select patients prior to considering intense therapy that could derive favorable long term benefits from this approach. Disclosures No relevant conflicts of interest to declare.